OncoMatch/Clinical Trials/NCT05870995
Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia
Is NCT05870995 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CALGE-VEN- RIC-conditioning for refractory leukemia.
Treatment: CALGE-VEN- RIC-conditioning — The investigators developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide (CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu to treat patients with refractory acute myeloid leukemia (AML). In this study, the aim is to further evaluate the efficacy and feasibility of the protocol with modifications: 1) reduced dose of CLAGE; 2) Reduced intensity conditioning (RIC) regimen as fludarabine, busulfan and melphalan (MBF) or total marrow irradiation (TMI); 3) Venetoclax was added to the chemotherapy and conditioning regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Lab requirements
Kidney function
abnormal renal function (Scr >1.5N) excluded
Liver function
abnormal liver function (enzyme >2N or bilirubin >2N) excluded
Cardiac function
poor cardiac function (EF<45%) excluded
patients with abnormal liver function (enzyme >2N or bilirubin >2N); patients with abnormal renal function (Scr >1.5N); patients with poor cardiac function （EF<45%）
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify